Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
Hepatitis A and B can be prevented with vaccines, and hepatitis C can be cured with antiviral treatment.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
A new classification system may more accurately reflect liver-related death trends in the United States.
People with liver cirrhosis often have substantial financial burden that interferes with their care.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.